An open-label trial of escitalopram in the treatment of pathological gambling

Clin Neuropharmacol. 2007 Jul-Aug;30(4):206-12. doi: 10.1097/wnf.0b013e31803d357f.

Abstract

Background: The effectiveness and tolerability of escitalopram was tested in the treatment of pathological gambling (PG).

Method: Nondepressed outpatients with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition PG received flexibly dosed escitalopram in a prospective, 10-week, open-label trial after a 2-week observation period. Subjects were evaluated at baseline and at 2-week intervals for assessment of gambling behavior, mood symptoms, and adverse experiences. The primary efficacy measure was the Yale-Brown Obsessive-Compulsive Scale modified for PG. Secondary efficacy measures included the Clinical Global Impression (CGI) Improvement and Severity Scales, a patient self-rated global rating, the Sheehan Disability Scale, and the Timeline Follow Back.

Results: Nineteen subjects (12 men and 7 women) had at least 1 postbaseline visit and were included in the analysis; 16 subjects (84%) completed the protocol. Significant improvement was found in all measures, including the Yale-Brown Obsessive-Compulsive Scale modified for PG, both CGI Scales, a patient self-rated global scale, the Timeline Follow Back, the Attention-Deficit/Hyperactivity Disorder Checklist, the Hamilton Depression Rating Scale, and all 3 Sheehan Disability Scale subscales. Fourteen subjects (73.7%) were considered responders (ie, achieved "much" or "very much" improvement on the CGI). Few adverse experiences were reported.

Conclusion: The results suggest that escitalopram is well tolerated and may be effective in the treatment of PG.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Antidepressive Agents, Second-Generation / therapeutic use*
  • Chi-Square Distribution
  • Citalopram / therapeutic use*
  • Disruptive, Impulse Control, and Conduct Disorders / drug therapy*
  • Disruptive, Impulse Control, and Conduct Disorders / psychology
  • Female
  • Gambling / psychology*
  • Humans
  • Male
  • Middle Aged
  • Prospective Studies
  • Severity of Illness Index

Substances

  • Antidepressive Agents, Second-Generation
  • Citalopram